Initial diagnosis | |
---|---|
Median age at BC diagnosis (years, range) | 51 (24-81) |
Invasive ductal carcinoma (patients, %) | 202/218 (92.7%) |
Median tumour size (mm, range) | 25 mm (1-200)* |
Presence of lymph node involvement (evaluable tumours, %) | 72/134 evaluable tumours (53.7%) |
Oestrogen receptor-positive (patients, %) | 93/192* (48.4%) |
Progesterone receptor-positive (patients, %) | 60/164* (36.6%) |
Treatments before CNS metastases | |
Chemotherapy before CNS metastases (patients, %) | 210/218 (96.3%) |
HER2-targeted therapy before CNS metastases (patients, %) | 197/218 (90.4%) |
Bevacizumab before CNS metastases (patients, %) | 3/218 (1.4%) |
Hormone therapy before CNS metastases (patients, %) (ER and PR positive at initial diagnosis N = 110 patients) | 82/110 (74.5%) |
Local radiation therapy before CNS metastases (patients, %) | 159/218 (72.9%) |
Metastatic disease | |
Median time to first metastatic relapse, any site (months, range) | 21.9 months (0-214.7) |
Median time between initial BC diagnosis and CNS metastasis (months, range) | 37.6 months (0-286.5) |
Median time to first relapse and CNS metastasis (months, range) | 12.9 months (0-283.7) |
CNS metastasis at first relapse (patients, %) | 39/217 (18%) |
Unique first site metastasis | 31/217 (14.3%) |
Carcinomatous meningitis | 28/216 (13%) |
CNS metastasis as secondary site (associated with other metastases) | 167/218 (76.6%) |
Other main metastatic sites at CNS metastasis diagnosis (n = 180) | |
Bone | 111/178 (62.4%) |
Lung/pleura | 86/178 (48.3%) |
Lymph nodes | 101/178 (56.7%) |
Liver | 34/178 (19.1%) |
Median interval between CNS metastasis and other metastases | 5.5 months (0.1-29) |
Survival following CNS metastasis | |
Median survival for study population (months, range) | 13.1 months (11-15.8) |
Median survival for CNS metastasis as first site of relapse | 14.2 months (10.6-22.2) |
Median survival for secondary CNS metastasis (associated with other metastases) | 13 months (10.5-15.8) |
Death at 2 years (Kaplan-Meier estimate) | 70.27 |
Median time to GPA threshold 1-2/2.5-3/3.5-4 patients | |
Score 1 - 2 | 10 months |
Score 2.5 - 3 | 12 months |
Score 3.5 - 4 | 24 months |